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Abstract 
The metabolic syndrome in HIV infected patients is particularly associated with the use protease inhibitors. 
Atazanavir is an inhibitor of the cytochrome P 450 (CYP) system, in particular CYP3A4 and CYP2C9 which can 
affect the metabolism of several drugs. To treat metabolic syndrome in HIV patients repaglinide is used and it is 
a short acting insulin secretagogues undergoing metabolism with CYP 3A4 and CYP 2C8 enzyme system. The 
purpose of this study was to assess the possible pharmacokinetic and pharmacodynamic drug interaction of 
repaglinide and atazanavir in healthy, diabetic and impaired hepatic function rats. Human oral therapeutic 
doses of atazanavir and repaglinide were extrapolated to rats based on the body surface area. The 
pharmacokinetic parameters and blood glucose concentrations of repaglinide were determined after oral 
administration of repaglinide alone (0.5 mg/kg) and in the presence of atazanavir (36 mg/kg) in normal, 
diabetic and hepatic impaired rats. The pharmacokinetics (PK) and blood glucose concentrations of repaglinide 
were significantly altered in the presence of atazanavir. The peak plasma concentration (Cmax), area under the 
plasma concentration time profile (AUC) and elimination half-life of repaglinide were significantly (P<0.0001) 
increased. The repaglinide clearance (CL) was significantly (P<0.0001) decreased in the presence of atazanavir 
treatment. In the presence of atazanavir, repaglinide hypoglycaemic activity was increased significantly 
(P<0.0001) when compared with the repaglinide control group. The present study demonstrated the significant 
difference in the PK/PD changes due to the enhanced bioavailability and decreased total body clearance of 
repaglinide may be due to the inhibition of the CYP P450 metabolic system, OATP and P-gp transporters by 
atazanavir. 
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Introduction 
The prevalence and incidence of metabolic syndrome, particularly diabetes mellitus, was increasing in 
HIV patients. Treatment of HIV-infected patients with HIV-1 protease inhibitors (PIs) as part of highly active 
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antiretroviral therapy (HAART) has contributed considerable reductions in HIV viral load and increased in 
CD4 lymphocyte numbers, thereby slowing disease progression and improving patient survival. However, 
despite this clinical success, it is recognized that PI-based therapy is correlated with a number of significant 
metabolic complications, including lipodystrophy, hyperlipidaemia, and insulin resistance. Around 80 % of 
patients who receive PIs develop insulin resistance leading to diabetes mellitus [1]. Drugs are primarily 
eliminated from the body by metabolism and excretion. In these two biologic processes, the liver plays a 
vital role in the metabolism of parent drugs and formation of metabolites prior to their excretion by the 
kidneys. The overall capacity of the liver to carry out its metabolic role is primarily dependent on three 
factors: activity of the metabolizing enzymes within the smooth endoplasmic reticulum and the cytosol of 
the hepatocytes; the degree of protein binding in the blood, which affects the amount of unbound drugs 
available for uptake into the hepatocytes; and liver blood flow, which delivers drugs to the hepatocytes via 
the portal vein for orally administered drugs and via the systemic circulation for all administered drugs. In 
hepatic impairment, patient-specific factors that affect enzymatic activity, protein binding, or liver blood 
flow would potentially result in significant alterations in drug disposition and therapeutic response. An 
understanding of the pharmacokinetic basis of hepatic drug elimination is helpful to conceptualize and 
quantify altered drug disposition in patients with liver dysfunction [2]. 
In hepatic dysfunction, the disruption of the liver vascular architecture may lead to increased blood flow 
resistance, which limits blood flow through the liver and causes portal vein pressure to rise. As a 
consequence, the formation of portocaval shunts may occur that allow the drug to bypass the first pass in 
the liver, which increase the systemic bioavailability of drugs. Chronic hepatic disease causes damage to 
hepatocytes; this in turn may cause a decreased intrinsic clearance of the drug metabolizing liver enzymes. 
Different CYP may be affected differently by the hepatocytes damage. In addition, the damage may also be 
different in the different regions of the liver. Cholestasis will impair the elimination of drugs that are 
excreted in the bile. Liver dysfunction causes a decrease of albumin in serum, which implies variation of the 
binding of drugs to the circulating proteins and can potentially affect the distribution volume of certain 
drugs [3]. 
Pharmacotherapy in patients with impaired hepatic function is an important and difficult aspect of 
medical practice. The elimination of many drugs takes place by inactive, active, or toxic metabolites may be 
significantly altered by hepatic dysfunction and dosage must be evaluated carefully. The presence of liver 
dysfunction that leads to increased plasma drug or metabolite concentrations may increase the prospect of 
toxicity which results in more complex drug-drug interaction. Hence, the preferred approach to prescribing 
medications for hepatic impaired patients is to select drugs that have predictable pharmacokinetic 
properties, are minimally affected by hepatic impairment and have a low potential for drug interactions 
with other drugs [4]. Safe pharmacological treatment of these complications requires an understanding of 
the drug-drug interactions between antiretroviral drugs and the drugs used in the treatment of diabetes 
[5]. 
Repaglinide is short acting anti diabetic drug used to normalize postprandial glucose concentrations in 
patients with type II diabetes mellitus [6]. Repaglinide is a substrate of the influx transporter OATP1B1 and 
metabolized mainly by CYP3A4 and CYP2C8. Pharmacokinetic drug interactions were observed in 
repaglinide with drugs which are inhibitors of CYP3A4, CYP2C8 and OATP1B1. Recently, a number of DDIs 
caused by the inhibition and induction of drug transporters have also been reported. Among these 
transporters, OATP1B1 is responsible for the influx of many therapeutic drugs in the liver; there have been 
a large number of reports on DDI caused by inhibition and induction of this transporter [7-8]. Protease 
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inhibitors are the potent inhibitors of CYP 3A4 and OATP transporters. Several DDIs were noticed when 
protease inhibitors (PIs) co-administered with drugs metabolized by CYP 3A4. Repaglinide also has an 
affinity for P-gp and it can contribute significantly to potential drug-drug interactions with other P-gp sub-
strates or inhibitors, hence the co-administration of repaglinide with the known P-gp inhibitor, 
cyclosporine A resulted in a significant increase in the plasma concentrations of repaglinide in human [9]. 
The protease inhibitors (PIs) are also potent mechanism based inhibitors, of which atazanavir is most 
potent substrate and potent inhibitor of the cytochrome P450 (CYP) system, in particular CYP3A4 and 
CYP2C9 and affect the metabolism of several drugs [10]. 
Atazanavir is an azapeptide HIV-I protease inhibitor approved by FDA for the combination of HIV-I 
infection. Atazanavir is metabolized by CYP3A4, as a substrate; however atazanavir interacts with drug 
transporter proteins. The study by Mothanje Barabara Lucia et al indicated that Atazanavir is a possible 
inhibitor for P-glycoprotein and competitively inhibits their efflux activity in a dose dependent manner [11]. 
In the present study, we hypothesize that the repaglinide elimination would be effected by OATP and P-
gp transporters, which makes available for the metabolism by CYP3A4. Atazanavir can inhibit CYP 3A4, 
CYP2C9 enzymes and it is OATP, P-gp inhibitor. Hence, the inhibition of transporter mediated hepatic 
uptake and metabolism may change the pharmacokinetics of repaglinide. However, there seem to be no 
published studies reported so far, so in the current study we have evaluated the influence of atazanavir on 
the pharmacokinetics and pharmacodyamics of repaglinide in normal, diabetic and hepatic impaired rats. 
Experimental  
Drugs and chemicals 
Repaglinide a gift sample obtained from Dr. Reddy’s Lab (Hyderabad, India) and atazanavir from 
Aurobindo Labs (Hyderabad, India). Alloxan monohydrate was purchased from Sigma Aldrich, Bangalore 
(Bangalore, India). Glucose kits purchased from Agappe diagnostics, (Mumbai, India). Acetonitrile HPLC 
grade and formic acid were obtained from Merck Chemicals (Mumbai, India). HPLC system: Agilent 
Technologies (California, USA) and MS/MS API-3200 mass spectrometer Sciex technologies (Foster City, CA, 
USA), HPLC column: Hypersil GOLD C18, 5µ column 4.6 * 100 mm internal diameter Thermo scientific, 
(North America). Vortex mixer and centrifuge were obtained from Remi laboratory instruments (Mumbai, 
India). Hematocrit heparinized rat bleeding capillaries was purchased from Top-Tech lab equipments Pvt 
Ltd (Hyderabad).  
Pharmacokinetics and Pharmacodynamic interaction study in normal rats 
Male albino Wistar rats weighing 200-250 gm were obtained from the Mahaveera enterprises 
(Hyderabad, India). They were housed under standard conditions and were maintained under a 12 hour 
light/dark cycle in the laboratory animal recourses facilities, Creative Educational Society’s college of 
pharmacy, Kurnool, India. Rats were fasted overnight before dosing and until 4 hours after dosing. Water 
was allowed ad libitum during the fasting period. The experiments were performed after prior approval of 
the study protocol by the institutional animal ethics committee. The study was conducted in accordance 
with the guidelines provided by the committee for the purpose of control and supervision of experiments 
and animals (CPCSEA). Rats were divided into 5 groups (n=6, each):  
Group-1: Repaglinide oral control group administered 0.5 mg/kg [12], 
Group-2: Atazanavir oral control group administered 36 mg/kg [13], 
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Group-3: Atazanavir (36 mg/kg) administered, followed by repaglinide (0.5 mg/kg) to normal rats,  
Group-4: Atazanavir (36 mg/kg) administered, followed by repaglinide (0.5 mg/kg) to diabetic induced rats,  
Group-5: Atazanavir (36 mg/kg) administered, followed by repaglinide (0.5 mg/kg) to a hepatic impaired 
rats.  
Required amount of drugs (repaglinide and atazanavir) were weighed and placed in two separate 
motor’s triturated with pestle, to this required amount of tween 80 was added as a wetting agent and 
triturated well until the whole compound was wet, then 0.5 % of methyl cellulose was added in gravimetric 
dilution method and triturated uniformly. This suspension was administered to the respective group of 
animals through oral gavage [14]. Blood samples collected retro-orbital puncture at 0, 0.25, 0.5, 1, 2, 4, 6, 
8, 12 and 24 h [15]. Plasma was separated by centrifugation using Remi research centrifuge at 4000 rpm 
for 10-20 min. Blood glucose levels were determined using Glucose oxidase peroxidase (GOD-POD) method 
by measuring optical density spectrophotometrically at 510 nm [16] and the remaining samples were 
stored in vials at -80 °C until LC/MSMS analysis. 
Pharmacokinetics and pharmacodynamic interaction study in diabetic rats 
Diabetes was induced in rats by the administration of alloxan monohydrate in ice cold normal saline, in 
two doses, that is 100mg and 50 mg/kg body wt intraperitoneally for two consecutive days [17]. After 72 h, 
the samples were collected from rats by retro-orbital puncture of all surviving animals and the plasma was 
analyzed for glucose levels. Rats with blood glucose levels of 200 mg/dl and above were considered as 
diabetic and selected for the study. Similarly a separate set of one group (n=6) was used for the 
pharmacodynamic interaction study with pretreated atazanavir (36 mg/kg) followed by 0.5 mg/kg 
repaglinide in diabetic rats. 
Pharmacokinetics and Pharmacodynamic interaction study in hepatic impaired rats 
Hepatic impairment was induced in rats by administration of carbon tetrachloride in olive oil (2ml/kg) 
intraperitoneally for one day [18]. After 24 h, blood samples were collected from rats by retro-orbital 
puncture of all surviving animals and the serum was analysed for total bilirubin (>2mg/dl), alanine 
transaminase (>150 mg/dl), aspartate transaminase (>200mg/dl) and albumin (<3 mg/dl) were selected for 
the study [19]. Similarly, a separate set of one group (n=6) was used for the pharmacodynamic interaction 
study with pretreated atazanavir (36 mg/kg) followed by 0.5 mg/kg repaglinide in hepatic impaired rats. 
Liquid chromatography-mass spectrometry analysis 
In vivo samples were prepared by protein precipitation with the addition of 200 µL acetonitrile 
containing an internal standard (rosuvastatin) to 50 µL sample volume. Samples were vortexed and 
centrifuged at 4000rpm for 10 min prior to evaporation of the supernatant. Atazanavir and repaglinide 
concentrations from plasma samples were measured using validated liquid chromatography/mass 
spectrometry (LC-MS/MS) method. Positive-ion multiple reaction monitoring was used for the tandem 
mass spectrometric detection of repaglinide, atazanavir and rosuvastatin. The selected [M+H] + precursor 
ions were m/z 453.2 for repaglinide, m/z 705.5 for atazanavir, and m/z 482.3 for rosuvastatin, and the 
product ions monitored were at m/z 230.3, 168.2 and 258.15 for repaglinide, atazanavir and rosuvastatin 
(internal standard), respectively. The high-performance liquid chromatography column was a Hypersil 
GOLD C18 (4.6x100mm,5µ) maintained at 40 °C with a flow rate of 1.3 mL/min. Mobile phase consisted of 
0.1 % formic acid in milliQ water (A) and  acetonitrile (B). A gradient elution was used. The overall run time 
was 6.0 min. An aliquot of 5 μl was injected at a mobile phase flow rate of 1300 μl/min. The liquid 
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chromatography was interfaced to API 3200 (Absciex, CA) ion-trap mass spectrometer operated in the 
positive ion electrospray and full tandem mass spectrometry mode. Before analyzing plasma, atazanavir 
and repaglinide standard solutions prepared in acetonitrile were run on LC to optimize the analysis and 
standardize calibration. Standard concentrations were chosen on the basis of levels found in plasma 
samples. The peak area ratio of analyte (repaglinide, atazanavir) to internal standard was plotted against 
analyte concentrations, and standard curves were fitted by weighted (1/x
2
) least-squares linear regression 
in the concentration of 9-20000 ng/mL for repaglinide and 19.5–20000 ng/mL for atazanavir. A correlation 
of 0.994 was desirable for all the calibration curves. The limit of quantitation for the purposes of this assay 
was 9 ng/mL and 19.5 ng/mL for repaglinide and atazanavir, respectively [20-21]. 
Pharmacokinetic and statistical analysis 
The pharmacokinetic parameters were obtained by fitting the plasma concentration-time data to non-
compartmental model by using (Phoenix -v6.3.0.395; Pharsight, Mountain view, CA). The maximum plasma 
concentration (Cmax) and the time to reach the same (Tmax), the half-life of plasma drug elimination (t1/2) 
was the ratio of 0.693 to the slope obtained by log-linear regression of the terminal phase of the drug 
plasma profile and the area under the concentration-time curve to terminal time (AUC0-t),area under the 
concentration-time curve to infinite time (AUC0-∞) was calculated by the linear/log trapezoidal rule and the 
total plasma clearance (CL) were  calculated by phoenix software. Data were expressed as a 
mean±standard deviation (SD). The significance was determined by applying one way ANOVA analysis. The 
results were considered to be statistically significant when p<0.0001. 
Glucose reduction calculations 
Percentage Reduction in BGL = {(IBGL – FBGL) / IBGL} x 100 
where BGL = blood glucose level; IBGL = initial blood glucose level; FBGL = final blood glucose level [22]. 
Results  
LC-MS/MS analytical method validation  
The analysis of plasma samples was completed after thorough validation of LC-MS/MS method. No 
interfering peaks were observed in blank plasma chromatograms at atazanavir and repaglinide retention 
time indicating the selectivity of the present method. The calibration curves and linearity of repaglinide 
(19.5-20000 ng/ml) and atazanavir (19-20000 ng/ml) samples was determined using weighted (1/x2) linear 
regression analysis. The correlation coefficients were 0.994 for calibration curves. The retention times for 
atazanavir, repaglinide and internal standard were 3.0, 3.5 and 3.3 min, respectively. Quality control (QC) 
samples were prepared at low, medium, and high concentrations to assess accuracy, precision and 
recovery. Intraday precision from a measurement of a minimum of six replicates was <7.1 % in rat plasma. 
The inter-day precision was determined from analysis of standard samples on three consecutive days and 
the relative standard deviation was found to be <6.9 % and <9 % for atazanavir and repaglinide, 
respectively. The overall accuracy of QC samples was in the range of 90-110 %. Percentage recovery was 
calculated as a ratio of the peak areas of drug in the matrix and the corresponding peak area of drug in 
acetonitrile. In plasma samples, greater than 85 % drug recovery was accomplished for both atazanavir and 
repaglinide. The lower limit of quantification (LOQ) was determined based on intra-run accuracy of LOQ 
replicates. The tested LOQ values were 9 ng/mL and 19.5 ng/mL for repaglinide and atazanavir, 
respectively, in rat plasma. 
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Effect of atazanavir on the pharmacokinetics and pharmacodynamics of repaglinide in normal rat 
Mean plasma concentration of repaglinide in the absence and presence of atazanavir in normal rats is 
shown in Figure 1. Mean pharmacokinetic parameters of repaglinide alone and in the presence of 
atazanavir in normal rats were shown in Table 1 (Column I and II). The pharmacokinetic parameters of 
repaglinide like AUC, Cmax, and clearance were altered significantly with single dose treatment of atazanavir 
in normal rats when compared to repaglinide treated group. Compared to the repaglinide control group 
(repaglinide alone) atazanavir increased 2-fold peak plasma concentration (Cmax), 11-fold area under the 
plasma concentration time curve (AUC0-t  and AUC0-∞) of repaglinide and atazanavir relative decrease in the 
total body clearance by 6 folds. Repaglinide produced a hypoglycemic effect which was indicated by 
percentage reduction levels in normal rats. The hypoglycemic effect of repaglinide enhanced when given in 
combination with atazanavir. It was indicated by a significant increase in percentage glucose reduction in 
comparison to repaglinide alone treated group in normal rats were shown in Table 2 and Figure 4. 
 
Figure 1. Plasma concentration-time curves of repaglinide following its oral administration (0.5 mg/kg) in 
control and atazanavir (36 mg/kg) pretreated normal rats. Data are expressed as mean ±SD in six rats. 
 
Table 1. Plasma concentration time profiles of repaglinide following its oral administration at 0.5 mg/kg in control and 






Repaglinide in the 
presence of atazanavir in 
normal rats 
Repaglinide in the 
presence of atazanavir 
in Diabetic rats 
Repaglinide in the 
presence of 
atazanavir in Hepatic 
impaired rats 
Cmax (ng/mL)       536 ± 30   1089 ± 123*** 2753 ± 7 ***  3410 ± 64  *** 
Tmax (h)            0.25 ± 0.00   4.0 ± 0.0 ** 4.0 ± 0.0 ** 0.5 ± 0.0   
AUC0-t (ng/mL.h)   678 ± 51   8031 ± 274*** 12602 ± 227***   18301 ± 151***  
AUCtotal(ng/mL.h)  726 ± 55   8044 ± 265*** 12722 ± 209 ***  19101 ± 184***   
Oral T1/2 (h)       3.0 ± 0.1   2.6 ± 0.1 3.5± 0.1   6.2 ± 0.3 ** 
Oral CL 
(mL/min/kg) 11 ± 1   1.03 ± 0.03*** 0.44  ± 0.01***   0.65 ± 0.01 ***  
*** Significant at P<0.0001 compared to repaglinide control (alone) group. 
**Significant at P<0.0001 compared to repaglinide control (alone) group 
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Effect of atazanavir on the pharmacokinetics and pharmacodynamics of repaglinide in diabetic rats 
Mean plasma concentration of repaglinide in the absence and presence of atazanavir in diabetic rats is 
shown in Figures 2 & 3. Mean pharmacokinetic parameters of repaglinide and atazanavir in diabetic rats 
are shown in Table 1 (column I and III). The pharmacokinetic parameters of repaglinide like AUC, Cmax, and 
clearance were altered significantly with single dose treatment of atazanavir in diabetic rats when 
compared to repaglinide treated group. Compared to the repaglinide control group (repaglinide alone) 
atazanavir increased 5-fold peak plasma concentration (Cmax), 18-fold area under the plasma concentration 
time curve (AUC0-∞) of repaglinide and atazanavir relatively decreases in the total body clearance by 25-
fold. Repaglinide produced a hypoglycemic effect indicated by percentage reduction levels in diabetic rats. 
The hypoglycemic effect of repaglinide exaggerated when given in combination with atazanavir, it was 
indicated by a significant increase in percentage glucose reduction in comparison to repaglinide alone 
treated group in normal rats were shown in Table 2 and Figure 4. 
 
Table 2. Mean percentage blood glucose reduction of repaglinide following its oral administration at 0.5mg/kg in 
control and atazanavir (36 mg/kg) pretreated normal, diabetic and hepatic impaired rats. Data are expressed as 




Repaglinide in the 
presence of 
atazanavir in normal 
rats 
Repaglinide in the 
presence of atazanavir 
in Diabetic rats 
Repaglinide in the 
presence of atazanavir 
in Hepatic impaired 
rats 
Time, h Mean±SD Mean±SD Mean±SD Mean±SD 
0.25 37.07±3.80 17.70±5.91 15.76±4.77*** 43.95±2.32*** 
0.50 25.12±5.84 37.21±22.51* 33.27±24.79*** 64.62±3.31*** 
1 19.76±5.99 43.12±15.56** 28.25±2.38*** 57.15±2.04*** 
2 7.03±5.02 44.50±6.84** 53.88±2.93*** 46.54±1.72*** 
4 9.63±3.65 59.22±7.72** 65.89±1.27*** 38.45±5.03*** 
6 12.57±5.11 47.72±5.50** 31.13±3.25*** 23.54±4.18*** 
8 3.47±3.67 38.38±3.03** 16.86±2.29*** 14.47±15.70*** 
12 2.28±6.66 27.75±6.10** 10.69±3.81*** 9.14±10.03*** 
24 0.34±5.34 12.24±3.84* 4.82±3.24*** 3.71±11.59*** 
*** Significant at P<0.0001 compared to repaglinide control (alone) group. 
** Significant at P<0.005 compared to repaglinide (alone) control group. 
Effect of atazanavir on the pharmacokinetics and pharmacodynamics of repaglinide in hepatic rats 
Mean plasma concentration of repaglinide in the absence and presence of atazanavir in hepatic 
impaired rats has shown in Figures 2 & 3. Mean pharmacokinetic parameters of repaglinide in the presence 
of atazanavir in hepatic impaired rats were shown in Table 1 (column I and IV). The pharmacokinetic 
parameters of repaglinide like AUC, Cmax, t1/2, clearance were altered significantly by a single treatment of 
atazanavir in normal rats when compared to repaglinide treated group. In a single dose study with 
atazanavir, increases in pharmacokinetic parameters of repaglinide are as follows: AUC (26-fold), Cmax (6-
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fold) with a relative decrease in total body clearance of 16-fold. The hypoglycemic effect of repaglinide 
enhanced when given in combination with atazanavir, it was indicated by a significant increase in 
percentage glucose reduction in comparison to repaglinide alone treated group in normal rats (see Table 2 
and Figure 4).   
  
Figure 2. Plasma concentration - time curves of repaglinide following its oral administration at 0.5 mg/kg in 
control and atazanavir (36 mg/kg) pretreated a) diabetic and b) hepatic impaired rats. Data are expressed as 
mean ±S.D. in (n=6) rats. 
 
Figure 3. Plasma concentration - time curves of repaglinide following its oral administration at 0.5 mg/kg in 
control and atazanavir (36 mg/kg) pretreated normal, diabetic and hepatic impaired rats. Data are expressed 
as mean ±S.D. in (n=6) rats. 
Discussion 
The most challenging aspect in treating HIV patients are to give the safe combination of drugs during 
the therapy because the HIV therapy regimen contains one nucleoside reverse transcriptase inhibitor, one 
non-nucleoside reverse transcriptase inhibitor and two protease inhibitors to reduce the viral load in the 
patients. The HIV patients will also have several other co-morbid conditions like Kaposi’s sarcoma, 
lymphoma, and tuberculosis. Apart from this the highly active antiretroviral is encountered with the 
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increase in prevalence of diabetes mellitus includes insulin resistance and glucose tolerance. The 
development of these metabolic syndromes like glucose and lipid disturbances presents a pharmacological 
challenge because of the possible pharmacokinetic drug-drug interactions associated with oral 
hypoglycemics and antiretroviral drugs. There are limited published data on drug interactions between 
antidiabetic medications and antiretroviral agents. In this investigation we studied the influence of 
atazanavir on the pharmacokinetics and pharmacodynamics of repaglinide at therapeutic doses in healthy, 
diabetic and hepatic impaired rats. The healthy rat model served to quickly identify the interaction and the 
diabetic and hepatic impaired model to validate the same response in the disease condition.   
Repaglinide is extensively metabolized by the hepatic cytochrome P450 enzyme system, particularly 
with CYP3A4; CYP2C8 with less than 2 % of an oral dose excreted unchanged in humans. Among this 
CYP3A4 has been identified as an important enzyme in the in-vitro metabolism of repaglinide [23]. The 
repaglinide pharmacokinetics was further complicated because of active hepatic uptake of repaglinide by 
OATP uptake transporter and it is a substrate for the OATP transporter [24]. Repaglinide also act as a 
substrate for P-glycoprotein which can significantly contribute to potential drug-drug interactions with 
other P-gp substrate or inhibitors [25]. 
 
Figure 4. Mean percentage blood glucose reduction curves of repaglinide following its oral administration at 
0.5 mg/kg in control and atazanavir (36 mg/kg) pretreated normal, diabetic and hepatic impaired rats. Data 
are expressed as mean ±S.D. in (n=6) rats.  
HIV protease inhibitors have identified as a substrates, inhibitors or inducers of CYP3A4, OATP and P-gp. 
Atazanavir is an extensively metabolized mainly by Cytochrome P450 enzyme system which have capable 
of altering both P-gp and CYP 3A4 activity in-vitro [26]. Atazanavir inhibits P-gp mediated transport and 
acts as a potent mechanism based inhibitor of CYP3A4 and it also inhibit the OATP transport particularly 
OATP1B1, OATP1B3 and OATP2B1 mediated transport in liver [27]. 
The pharmacokinetics (Cmax, AUC0-t, AUCt-∞, t1/2, clearance) and pharmacodynamics (percent blood 
glucose reduction) of repaglinide were significantly altered in the atazanavir treated normal, diabetic and 
hepatic impaired rats. The significant improvement of Cmax and AUC of repaglinide in healthy, diabetic and 
hepatic impaired rats could be due to CYP enzyme and P-gp mediated transport inhibition during the first 
pass metabolism. Compared to the control group the atazanavir significantly decreased the clearance of 
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repaglinide in healthy, diabetic and hepatic impaired rats, this could be due to the inhibition of CYP enzyme 
and OATP transporter in the liver. 
The magnitude change in the exposure of repaglinide is more in hepatic impaired rats could be due to 
the synergistic effect of OATP inhibition by atazanavir and liver dysfunction 
The clearance of repaglinide was significantly decreased in normal and diabetic rats, which was due to 
the inhibition of CYP enzyme and OATP, P-gp transport by atazanavir. However, in hepatic impaired rats 
the magnitude change in the exposure of repaglinide was more, which could be due to the synergistic 
effect of OATP inhibition by atazanavir and liver dysfunction. In hepatic impaired rats t1/2 of repaglinide was 
increased significantly when compared to the repaglinide alone control group due to decrease in clearance 
of repaglinide.  
The blood glucose levels were decreased significantly when repaglinide is given in combination with 
atazanavir in normal, diabetic and hepatic impaired groups. The increased bioavailability (AUC and Cmax) of 
repaglinide when administered with atazanavir increases the plasma levels of repaglinide and decreases 
elimination which results in enhanced mean blood glucose percentage which may further precipitate 
hypoglycemic action. 
Our findings were consistent with the report by Shitara, et al reported gemfibrozil increased the AUC of 
repaglinide approximately 8-fold and prolonged its t1/2 from 1.3 to 3.7 in healthy subjects [28]. Gemfibrozil 
is a strong inhibitor of CYP2C8 in vivo mainly due to its 1-O-ß-glucuronide metabolite. Gemfibrozil and its 
glucuronide inhibit the OATP1B1 in vitro, suggesting that the involvement of drug-drug interaction 
between gemfibrozil and repaglinide [28]. Kajossari et al reported that the co-administration of repaglinide 
along with the known P-glycoprotein inhibitor cyclosporine A raised the plasma concentrations of 
repaglinide significantly, probably by inhibiting its CYP3A4-catalyzed biotransformation and OATP1B1-
mediated hepatic uptake. Cyclosporine may enhance the blood glucose-lowering effect of repaglinide and 
increase the risk of hypoglycemia in humans [29]. 
Conclusions 
In this study, atazanavir enhanced the bioavailability of repaglinide after oral administration, this 
enhanced bioavailability of repaglinide might be mainly due to the possible inhibition of CYP enzyme 
mediated metabolism and P-glycoprotein effect in the intestine and in the liver the reduced the total body 
clearance of repaglinide is due to CYP enzyme  and OATP mediated transport inhibition. The current study 
has raised awareness of potential drug-drug interaction between the repaglinide and atazanavir in normal, 
diabetic and hepatic impaired groups. The clinical significance of this study should be further evaluated in 
clinical studies. 
References 
[1] J.C. Koster, M.S. Remedi, H. Qiu, C.G. Nichols, P.W. Hruz, Diabetes 52 (2003) 1696-1700. 
[2] J.T. DiPiro, R.L. Talbert, G.C. Yee, G.R. Matzke, Pharmacotherapy: A Pathophysiologic Approach, 
Seventh Edition, McGraw-Hill Education, LLC. Page No: 693-704. 
[3] M. Gonzalez, L. Goracci, G. Cruciani, I. Poggesi. Expert Opinion Drug Metabolism Toxicology 10 
(2014) :1397-1408. 
[4] G.M. Ferron, R.A. Preston, R.J. Noveck, P. Pockros, P. Mayer, J. Getsy, M. Turner, M. Abell, J. Paul, 
Clinical Therapeutics 23 (2001) 1180-1192. 
ADMET & DMPK 4(3) (2016) 269-279 PK and PD interaction between repaglinide and atazanavir 
doi: 10.5599/admet.4.3.328 279 
[5] S.K. Mastan, G. Chaitanya, K. R. Reddy, K.E. Kumar. International Journal of PharmTech Research 1 
(2009) 613-622. 
[6] C.R. Culy, B. Jarvis. Drugs 61 (2001) 1625–60. 
[7] A. Tornio, M. Niemi, P.J. Neuvonen, J.T. Backman. Trends in pharmaceutical sciences 33 (2012) 312-
321. 
[8] T.B. Bidstrup, I. Bjørnsdottir, U.G. Sidelmann, M. Søndergård, T. Kristian, T. Hansen. British Journal 
of Clinical Pharmacology 56 (2003) 305–314.   
[9] J.S. Choi, I. choi, D.H. Choi. Pharmacological Reports 65 (2013) 1422-1430. 
[10] E.S. Perloff, S.X. Duan, P.R. Skolnik, D.J. Greenblatt, L.L. Von Moltke. American society of 
pharmacology and experimental therapeutics 3 (2005) 764-770. 
[11] M.B. Lucia, C. Golotta, S. Rutella, E. Rastrelli, A. Savarino, R. Cauda. Journal of Acquired immune 
deficiency syndrome 39 (2005) 635-637. 
[12] D.-H. Choi, J.-S. Choi, Korean Journal of Clinical Pharmacology 21 (2011) 215-223. 
[13] S.K. Mastan, K.E. Kumar. International journal of Diabetes mellitus 2 (2010) 56-60. 
[14] S.N. Bhattachar, D.M. Bender, S.A. Sweetana, J.A. Wesley, Discovering and Developing Molecules 
with Optimal Drug-Like Properties. A.C. Templeton, editor. Discovery Formulations: Approaches and 
Practices in Early Preclinical Development, Discovering and Developing Molecules with Optimal 
Drug-Like Properties. Springer New York: AAPS Press, 2015 Page no: 49-94. 
[15] V. Riley, Proceedings of The Society for Experimental Biology and Medicine 104 (1960)751–754. 
[16] P. Trinder. Journal of Clinical Pathology 22 (1969) 158–161. 
[17] R.E. Heikkila, European Journal of Pharmacology 44 (1977) 191-193. 
[18] S. Robin, K. Sunil, A.C. Rana, S. Nidhi, International research journal of pharmacy 3 (2012) 86-95.  
[19] C. Johnson-Delaney, Zoological Education Network (1996) 220-250. 
[20] L. Xiao-Rong, D. Xiao-Jian, Z. Yi-Fan, D. Jue-Fang, C. Xiao-Yan, Z. Dafang, Acta Pharmaceutica Sinica 
48 (2013) 547 −553. 
[21] G. Singh, R.S. Pai, S. Mustafa. Journal of chromatographic separation techniques 5 (2015) 1-5. 
[22] P. Neerati, J. Gade. European Journal of Pharmaceutical Sciences 42 (2011) 285–289. 
[23] P.N. van Heiningen, V. Hatrop, K. Kramer Nielsen, K.T. Hansen, J.J. van Lier, N.C. De Merbel, B. 
Oosterhuis, J.H.G. Jonkman. European journal of clinical pharmacology 55 (1999) 521-525. 
[24] C. Sall, J. Brian Houston, A. Galetin. The American society for pharmacology and experimental 
therapeutics 40 (2012) 1279-1289. 
[25] C.K. Lee, J.S. Choi, J.S. Bang. Korean Journal of Physiology and Pharmacology 17 (2013) 245-251. 
[26] E.S. Perloff, S.X. Duan, P.R. Skolnik, D.J. Greenblatt, L.L. von Moltke. The American Society for 
Pharmacology and Experimental Therapeutics 33 (2005) 764-770. 
[27] L. Griffin, P. Annaert, K.L.R. Brower. Journal of Pharmaceutical Sciences 100 (2011) 3636-3654. 
[28] Y. Shitara, M. Hirano, H. Sato, Y. Sugiyama, Journal of Pharmacology and Experimental 
Therapeutics 311 (2004) 228–236. 
[29] L.I. Kajosaari, M. Niemi, M. Neuvonen, J. Laitila, P.J. Neuvonen, J.T. Backman. Clinical Pharmacology 




©2016 by the authors; licensee IAPC, Zagreb, Croatia. This article is an open-access article distributed under the terms and 
conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/)  
 
